Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARIZ Precision Medicine-PRDM2-siRNA-Prostate Cancer
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ARIZ Precision Medicine-PRDM2-siRNA-Prostate Cancer is an investigational siRNA therapeutic developed by ARIZ Precision Medicine for the treatment of prostate cancer. The drug utilizes small interfering RNA (siRNA) technology to knock down the expression of PRDM2 (PR domain zinc finger protein 2, also known as RIZ), an epigenetic regulator involved in cancer cell formation and progression. The therapeutic is delivered using ARIZ's proprietary ligand-targeted nanoparticle drug delivery system (T-DDS), which is designed to selectively deliver the siRNA payload to cancer cells while sparing healthy tissue. PRDM2 is part of a family of proteins that often function as tumor suppressors, and its dysregulation is an early driver in several solid tumors, including prostate cancer.
- Other names
- Prostate Cancer Program (PRDM2)PRDM2-siRNAPRDM-2-siRNAPRDM 2-siRNA
02
Targets
PRDM2 (PR domain zinc finger protein 2)
Beyond the preview
Go deeper on ARIZ Precision Medicine-PRDM2-siRNA-Prostate Cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARIZ Precision Medicine-PRDM2-siRNA-Prostate Cancer.